A rare autoimmune disease creates sudden pain in the abdomen or the head, sending a patient to the emergency room with a potentially fatal condition. The pain comes from a multitude of blockages of ...

The researchers noted that their paper is the first, to their knowledge, to report on a case of thrombocytopenic purpura (TTP) in a patient with metastatic renal cell carcinoma (RCC). Authors of a new ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...

Pregnancy-onset thrombotic thrombocytopenic purpura (TTP) is a challenging condition with 3 distinct subtypes, which should be planned for in adults with a history of TTP. Adults with a history of ...

The FDA approved the enzyme replacement therapy Adzynma for the prophylactic or on-demand treatment of adults and pediatric patients with congenital thrombotic thrombocytopenic purpura, a rare blood ...

− cTTP is an Ultra-rare, Potentially Fatal Blood-Clotting Disorder with Limited Treatment Options; Untreated, Acute TTP Events Have a Mortality Rate of >90%1,2 − Approval Based on Totality of Evidence ...

The US Food and Drug Administration (FDA) has approved the biologic Adzynma (ADAMTS13, recombinant-krhn, Takeda Pharmaceuticals) to treat adults and children who have a rare and life-threatening blood ...